Amanda L. Richer

Amanda L. Richer

Auto-generated profile, based on publicly available information

Amanda L. Richer

University of Colorado Anschutz 2 Department of Biochemistry and Molecular Genetics Aurora, Colorado

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
ARAmanda L. Richer
Amanda L. Richer
JCJacqueline M. Cala
Jacqueline M. Cala
KOKelley O'Brien
Kelley O'Brien
VCVashti M. Carson
Vashti M. Carson
LILandon J. Inge
Landon J. Inge
TWTimothy G. Whitsett
Timothy G. Whitsett
G1–S checkpoint loss contributes to carcinogenesis and increases reliance upon the G2–M checkpoint for adaptation to stress and DNA repair, making G2–M checkpoint inhibition a target for novel therapeutic development. AZD1775, an inhibitor against the critical G2–M checkpoint protein WEE1, is currently in clinical trials across a number of tumor types. AZD1775 and DNA-damaging agents have displayed favorable activity in several preclinical tumor models, often in the molecular context of TP53 loss. Whether AZD1775 efficacy is modulated by other molecular contexts remains poorly understood. The tumor suppressor serine/threonine kinase 11 (LKB1/STK11) is one of the most frequently mutated genes in non–small cell lung cancer (NSCLC) and is commonly comutated with oncogenic KRAS mutations. We investigated the preclinical effects of AZD1775 in the context of KRAS/LKB1 in NSCLC. Using NSCLC cell lines, we found that AZD1775 alone and in combination with DNA-damaging agents (e.g., cisplatin and radiation) decreased tumor cell viability in LKB1-deficient NSCLC cells. In vitro, LKB1 deficiency enhanced DNA damage and apoptosis in response to AZD1775 exposure compared with wild-type LKB1 cells. In a genetically engineered mouse model of mutant Kras with concomitant loss of Lkb1, combined AZD1775 and cisplatin extended overall survival compared with cisplatin alone. Our data suggest that lack of phosphorylation of LKB1 by ATM was involved in AZD1775-mediated cytotoxicity. Collectively, these findings provide a clinical application for AZD1775 with DNA-damaging agents in KRAS/LKB1 NSCLC. Cancer Res; 77(17); 4663–72. ©2017 AACR.

1 February 2015 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
TWTimothy G Whitsett
Timothy G Whitsett
ARAmanda L Richer
Amanda L Richer
JFJacqueline M Friel
Jacqueline M Friel
VCVashti M Carson
Vashti M Carson
LILandon J Inge
Landon J Inge
Lung cancer remains the leading cause of cancer-related mortality worldwide. The application of next-generation genomic technologies has offered a more comprehensive look at the mutational landscape across the different subtypes of non-small cell lung cancer (NSCLC). A number of recurrent mutations such as TP53, KRAS, and epidermal growth factor receptor (EGFR) have been identified in NSCLC. While targeted therapeutic successes have been demonstrated in the therapeutic targeting of EGFR and ALK, the majority of NSCLC tumors do not harbor these genomic events. This review looks at the current treatment paradigms for lung adenocarcinomas and squamous cell carcinomas, examining genomic aberrations that dictate therapy selection, as well as novel therapeutic strategies for tumors harboring mutations in KRAS, TP53, and LKB1 which, to date, have been considered “undruggable”. A more thorough understanding of the molecular alterations that govern NSCLC tumorigenesis, aided by next-generation sequencing, will lead to targeted therapeutic options expected to dramatically reduce the high mortality rate observed in lung cancer.

1 October 2014 in Cancer Letters
Verified
Journal Article
Closed access
LILandon J. Inge
Landon J. Inge
JFJacqueline M. Friel
Jacqueline M. Friel
ARAmanda L. Richer
Amanda L. Richer
AFAaron J. Fowler
Aaron J. Fowler
TWTimothy Whitsett
Timothy Whitsett
RBRoss M. Bremner
Ross M. Bremner

1 April 2015 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
AFAaron J. Fowler
Aaron J. Fowler
ARAmanda L. Richer
Amanda L. Richer
RBRoss M. Bremner
Ross M. Bremner
LILandon J. Inge
Landon J. Inge

30 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJoseph L Sottnik
Joseph L Sottnik
MSMadeleine Shackleford
Madeleine Shackleford
CNCamryn S. Nesiba
Camryn S. Nesiba
ARAmanda L. Richer
Amanda L. Richer
JSJordan M. Swartz
Jordan M. Swartz
MSMatthew Sikora
Matthew Sikora
Invasive lobular carcinoma of the breast (ILC) is typically estrogen receptor α (ER)-positive and presents with biomarkers of anti-estrogen sensitive disease, yet patients with ILC face particularly poor long-term outcomes with increased recurrence risk, suggesting endocrine response and ER function are unique in ILC. ER is co- regulated by the DNA repair protein Mediator of DNA Damage Checkpoint 1 (MDC1) specifically in ILC cells, driving distinct ER activity. However, this novel MDC1 activity is associated with dysfunctional canonical DNA repair activity by MDC1, but without typical features of DNA repair deficiency. To understand reciprocal activities of MDC1, we profiled the MDC1 interactome and found MDC1-associated proteins in ILC cells mirror a “BRCA-like” state lacking key homologous recombination (HR) proteins, consistent with HR dysfunction but distinct from classic “BRCAness”. HR dysfunction in ILC cells is supported by single-cell transcriptome and DNA repair activity analyses, with DNA repair signaling and functional data, showing dysfunctional induction and resolution of HR. In parallel, ILC tumor data are consistent with a distinct form of HR dysfunction via impaired HR resolution, lacking BRCA-like genomic scarring but showing elevated signatures of PARP inhibitor sensitivity. We demonstrate this HR dysfunction can be exploited using PARP inhibition, and found that talazoparib treatment produced a durable growth suppression both in vitro and in multiple ILC xenografts in vivo . ILC-specific ER:MDC1 activity creates a new context for ER and MDC1 function in ILC, at the cost of a DNA repair dysfunction, which may be therapeutically targetable. Significance: ILC is rarely associated with biomarkers of HR deficiency, and as such patients are rarely eligible for treatment with PARP inhibitors. Our work suggests ILC presents with a previously unappreciated form of HR dysfunction, linked to ILC-specific genomic activity of ER and MDC1, which imparts sensitivity to PARP inhibition.

29 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAmanda L. Richer
Amanda L. Richer
KRKent A. Riemondy
Kent A. Riemondy
LHLakotah Hardie
Lakotah Hardie
JHJay R. Hesselberth
Jay R. Hesselberth
Methods to measure heterogeneity among cells are rapidly transforming our understanding of biology but are currently limited to molecular abundance measurements. We developed an approach to simultaneously measure biochemical activities and mRNA abundance in single cells to understand the heterogeneity of DNA repair activities across thousands of human lymphocytes, identifying known and novel cell-type-specific DNA repair phenotypes. Our approach provides a general framework for understanding functional heterogeneity among single cells.